| Symbol | PALI |
|---|---|
| Name | PALISADE BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 5800 ARMADA DRIVE,SUITE 210, CARLSBAD, California, 92008, United States |
| Telephone | +1 858 704-4900 |
| Fax | — |
| — | |
| Website | https://www.palisadebio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001357459 |
| Description | Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bios innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - PALISADE BIO, INC. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001213900-26-088750 <b>Size:</b> 20 KB
Read morePalisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Read morePalisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Read more(30% Negative) PALISADE BIO, INC. (PALI) Reports Q3 2026 Financial Results
Read more📋 Jones Mitchell Lawrence (Officer) plans to sell 53K shares of PALISADE BIO, INC. (at $2.04 each, total $108K) Filed: Jul 07, 2026 | ID: 000267
Read more📋 Finley John David (Officer) plans to sell 147K shares of PALISADE BIO, INC. (at $2.07 each, total $303K) Filed: Jul 07, 2026 | ID: 000266
Read moreDirector Baltera Robert Jr. 🟢 acquired 30.0K shares of PALISADE BIO, INC. (PALI) at $1.98 Transaction Date: Jul 01, 2026 | Filing ID: 032229
Read morePalisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
Read more